Metagenomi Therapeutics, Inc. (MGX)

NMS – Real Time Price. Currency in USD

1.21

+0.00 (0.34%)

Market open: Aug 12, 2026, 10:02 AM EDT

1.21

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Stock details

Previous close: 1.2295$
Day's range: 1.18 - 1.25$
52-week range: 1.13 - 3.95$
Volume: 70 803
Average volume: 113 792
Beta: 1.39
EPS (TTM): -2.29
PE ratio (TTM): N/A
Forward P/E: N/A
Market cap: 46 286 812
Shares outstanding: 37 646 858
Dividend yield: N/A
Next earnings date: 2026-11-18
Sector: Healthcare
Industry: Biotechnology

About the company

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper trigly... read more

CEO: Jian Irish
Country: United States
IPO Date: 2024-02-09
Employees: 118
Fiscal Year End: January - December
Website: https://metagenomi.co

Revenue Breakdown

Ionis / 97.66%

Affini-T / 2.24%

Other / 0.10%

News

No Data

There are no news for this stock.

Chart: MGX

Loading Chart...

Overall Score

2.8 / 1028%

Octagon View

Strength & Weakness

Total debt $39.2M significantly exceeds cash reserves ($25.3M), raising financial stability concerns

Total current assets $144.6M exceed Total current liabilities $22.5M, highlighting excellent liquidity

Debt-to-equity ratio (0.3) is well below the industry average (0.3), showcasing prudent financial management

Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns

Negative free cash flow -$21.2M limits the company's ability to reinvest or pay down debt

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	6.43	6.05	10
Quick ratio	6.43	5.63	10
Debt to Equity	0.28	0.30	8.0
Debt to Assets	0.20	1.04	8.0
Interest coverage	N/A	-16.91	1.0
Weighted average score			7.4

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	17M	45M	52M	25M	22M
Gross Profit	15M	41M	47M	20M	17M
Operating Income	-45M	-78M	-89M	-96M	-93M
Net Income	-44M	-68M	-78M	-88M	-86M
EBITDA	-43M	-74M	-83M	-91M	-88M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	-2.16	-11.73	1.0
Operating margin %	-1970.11	-24.60	1.0
Net margin %	-1847.68	-172.20	1.0
EBITDA margin %	-1867.95	-201.27	1.0
Cash flow margin %	-1696.71	-156.39	1.0
Weighted average score			1.0

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	-30.49	-57.97	1.0
ROE	-43.00	-63.56	1.0
ROIC	-36.21	-42.57	1.0
ROCE	-11.23	-71.10	1.0
Weighted average score			1.0

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	-64.65	-2.42	1.0
Next quarter	-65.24	-0.06	1.0
Current year	-59.35	8.85	3.5
Next year	8.84	9.99	6.0
Weighted average score			2.9

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	-68.08	-2.35	-3.38	10.29	2.5
Y/Y	-69.75	7.91	10.29	8.34	5.0
3y average	41.76	-27.81	44.12	-244.45	5.5
5y average	N/A	N/A	N/A	N/A	1.0
Weighted average score					3.5

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	N/A	-5.25	1.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	2.06	64.66	6.4
P/B	0.34	2.96	10
Weighted average score			4.6

DCF Model

DCF Model Period5 years

Discount rate8.5%

Perpetual growth rate3%

Revenue 5 year CAGR790.49%

FCF 5 year CAGR4

Fair value135.19$

Stock price1.23$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$135.19

UndervaluedStock priceOvervalued

$1.23

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Jian Irish

Country

United States

IPO Date

2024-02-09

Employees

118

Fiscal Year End

January - December

Website

https://metagenomi.co

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

6.43

6.05

Quick ratio

6.43

5.63

Debt to Equity

0.28

0.30

8.0

Debt to Assets

0.20

1.04

8.0

Interest coverage

N/A

-16.91

1.0

Weighted average score

7.4

METRIC

2022

2023

2024

2025

TTM

Total Revenue

17M

45M

52M

25M

22M

Gross Profit

15M

41M

47M

20M

17M

Operating Income

-45M

-78M

-89M

-96M

-93M

Net Income

-44M

-68M

-78M

-88M

-86M

EBITDA

-43M

-74M

-83M

-91M

-88M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

-2.16

-11.73

1.0

Operating margin %

-1970.11

-24.60

1.0

Net margin %

-1847.68

-172.20

1.0

EBITDA margin %

-1867.95

-201.27

1.0

Cash flow margin %

-1696.71

-156.39

1.0

Weighted average score

1.0

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

-30.49

-57.97

1.0

ROE

-43.00

-63.56

1.0

ROIC

-36.21

-42.57

1.0

ROCE

-11.23

-71.10

1.0

Weighted average score

1.0

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

-64.65

-2.42

1.0

Next quarter

-65.24

-0.06

1.0

Current year

-59.35

8.85

3.5

Next year

8.84

9.99

6.0

Weighted average score

2.9

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

-68.08

-2.35

-3.38

10.29

2.5

Y/Y

-69.75

7.91

10.29

8.34

5.0

3y average

41.76

-27.81

44.12

-244.45

5.5

5y average

N/A

1.0

Weighted average score

3.5

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

N/A

-5.25

1.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

2.06

64.66

6.4

P/B

0.34

2.96

Weighted average score

4.6

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Metagenomi Therapeutics, Inc. (MGX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Metagenomi Therapeutics, Inc. (MGX)

Stock details

About the company

Revenue Breakdown

News

Chart: MGX

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$135.19

$1.23

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: MGX

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$135.19

$1.23

Economic Moat